Medtronic ICD Sales Better Than Expected, But Some Share Goes To St. Jude
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's sales of implantable cardioverter defibrillators beat analyst expectations in the most recent fiscal quarter despite lingering fall-out from the firm's October Fidelis ICD lead recall